- Home
- WDI vs ANAB Comparison
WDI vs ANAB Comparison
Compare WDI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- ANAB
- Stock Information
- Founded
- WDI 2021
- ANAB 2005
- Country
- WDI United States
- ANAB United States
- Employees
- WDI N/A
- ANAB N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- ANAB Health Care
- Exchange
- WDI Nasdaq
- ANAB Nasdaq
- Market Cap
- WDI 753.0M
- ANAB 621.1M
- IPO Year
- WDI N/A
- ANAB 2017
- Fundamental
- Price
- WDI $14.81
- ANAB $22.47
- Analyst Decision
- WDI
- ANAB Buy
- Analyst Count
- WDI 0
- ANAB 10
- Target Price
- WDI N/A
- ANAB $44.25
- AVG Volume (30 Days)
- WDI 192.6K
- ANAB 661.9K
- Earning Date
- WDI 01-01-0001
- ANAB 08-04-2025
- Dividend Yield
- WDI 11.80%
- ANAB N/A
- EPS Growth
- WDI N/A
- ANAB N/A
- EPS
- WDI 1.12
- ANAB N/A
- Revenue
- WDI N/A
- ANAB $111,872,000.00
- Revenue This Year
- WDI N/A
- ANAB N/A
- Revenue Next Year
- WDI N/A
- ANAB $24.39
- P/E Ratio
- WDI $12.82
- ANAB N/A
- Revenue Growth
- WDI N/A
- ANAB 387.20
- 52 Week Low
- WDI $12.16
- ANAB $12.21
- 52 Week High
- WDI $14.69
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- WDI 53.77
- ANAB 49.83
- Support Level
- WDI $14.53
- ANAB $22.49
- Resistance Level
- WDI $14.75
- ANAB $24.86
- Average True Range (ATR)
- WDI 0.11
- ANAB 1.27
- MACD
- WDI -0.04
- ANAB -0.17
- Stochastic Oscillator
- WDI 47.56
- ANAB 10.49
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).